Treatment of HBV/HCV coinfection (Q37694558)

22 August 2017

1 reference

title

Treatment of HBV/HCV coinfection (English)

1 reference

22 August 2017

2

Michael P Manns

1 reference

22 August 2017

3

Heiner Wedemeyer

1 reference

22 August 2017

Andrej Potthoff

1

1 reference

22 August 2017

language of work or name

English

0 references

publication date

1 April 2010

1 reference

Expert Opinion on Pharmacotherapy

22 August 2017

published in

1 reference

22 August 2017

volume

11

1 reference

22 August 2017

issue

6

1 reference

22 August 2017

page(s)

919-928

1 reference

Liver transplantation in patients with HIV infection.

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656561003637659

Hepatitis C virus infection in Eastern Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003637659

Clinical and virological profiles in patients with multiple hepatitis virus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003637659

The long-term course of chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003637659

Presence of hepatitis B and C viral genomes in US blood donors as detected by polymerase chain reaction amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003637659

Multiple viral hepatitis in injection drug users and associated risk factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003637659

Relationship of hepatitis B or C virus prevalences, risk factors, and outcomes in renal transplant recipients: analysis of German data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003637659

Hepatitis C virus infection as a risk factor for hepatocellular carcinoma in patients with cirrhosis. A case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003637659

A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003637659

HBV superinfection in hepatitis C virus chronic carriers, viral interaction, and clinical course.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003637659

Impact of acute hepatitis C virus superinfection in patients with chronic hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003637659

Causes of death after diagnosis of hepatitis B or hepatitis C infection: a large community-based linkage study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003637659

Hepatitis C virus (HCV) infection and liver-related mortality: a population-based cohort study in southern Italy. The Association for the Study of Liver Disease in Puglia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003637659

Controversies about occult hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003637659

Occult hepatitis B virus infection: a covert operation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003637659

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003637659

Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003637659

Co-infection by serologically-silent hepatitis B virus may contribute to poor interferon response in patients with chronic hepatitis C by down-regulation of type-I interferon receptor gene expression in the liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003637659

Diagnosis and clinical impact of occult hepatitis B infection in patients with biopsy proven chronic hepatitis C: a multicenter study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003637659

Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003637659

Serologically silent hepatitis B virus coinfection in patients with hepatitis C virus-associated chronic liver disease: clinical and virological significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003637659

Evidence for hepatitis B virus infection in patients with chronic hepatitis C with and without serological markers of hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003637659

The impact of previous HBV infection on the course of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003637659

Statements from the Taormina expert meeting on occult hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003637659

Occult HBV infection may represent a major risk factor of non-response to antiviral therapy of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003637659

Occult hepatitis B virus infection as a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C in whom viral eradication fails

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003637659

The clinical features of chronic hepatitis C are not affected by the coexistence of hepatitis B virus DNA in patients negative for hepatitis B surface antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003637659

Occult hepatitis B virus infection and clinical outcomes of patients with chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003637659

Occult hepatitis B virus infection in Lebanese patients with chronic hepatitis C liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003637659

Occult hepatitis B virus infection does not affect liver histology or response to therapy with interferon alpha and ribavirin in intravenous drug users with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003637659

Occult hepatitis B virus infection in Greek patients with chronic hepatitis C and in patients with diverse nonviral hepatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003637659

Impact of occult hepatitis B virus infection on efficacy and prognosis of interferon-alpha therapy for patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003637659

Transmission of serologically silent hepatitis B virus along with hepatitis C virus in two cases of posttransfusion hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003637659

Effect of concurrent acute infection with hepatitis C virus on acute hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003637659

Fulminant hepatic failure in acute hepatitis C: increased risk in chronic carriers of hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003637659

Epidemiological characteristics, risk factors, and clinical manifestations of acute non-A-E hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003637659

Hepatitis C virus superinfection in hepatitis B virus chronic carriers: a reciprocal viral interaction and a variable clinical course

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003637659

Hepatitis C virus-associated fulminant hepatic failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003637659

Clearance of HCV RNA in a chronic hepatitis C virus-infected patient during acute hepatitis B virus superinfection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003637659

Impact of acute hepatitis B virus superinfection on chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003637659

Hepatitis C Virus Infection in Chronic Hepatitis B Virus Carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003637659

Coinfection of hepatitis C virus in patients with chronic hepatitis B infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003637659

Role of Hepatitis C Virus Infection in Spontaneous Hepatitis B Surface Antigen Clearance during Chronic Hepatitis B Virus Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003637659

Role of hepatitis B, C, and D viruses in dual and triple infection: influence of viral genotypes and hepatitis B precore and basal core promoter mutations on viral replicative interference

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003637659

The significance of antibody to hepatitis C virus in patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003637659

Hepatitis C virus superinfection in patients with chronic hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003637659

Acute hepatitis C virus superinfection followed by spontaneous HBeAg seroconversion and HBsAg elimination

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003637659

Role of hepatitis C and delta viruses in the termination of chronic hepatitis B surface antigen carrier state: a multivariate analysis in a longitudinal follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003637659

Characteristics of patients with dual infection by hepatitis B and C viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003637659

Hepatitis C virus antibody and hepatitis C virus replication in chronic hepatitis B patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003637659

Long-term follow-up of hepatitis B virus and hepatitis C virus replicative levels in chronic hepatitis patients coinfected with both viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003637659

Longitudinal evaluation reveals a complex spectrum of virological profiles in hepatitis B virus/hepatitis C virus-coinfected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003637659

Suppression of hepatitis B virus enhancer 1 and 2 by hepatitis C virus core protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003637659

Hepatitis B virus and hepatitis C virus interaction in Huh-7 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003637659

Hepatitis B and C virus coinfection: a novel model system reveals the absence of direct viral interference

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003637659

New insights into hepatitis B and C virus co-infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003637659

Treatment of the hepatitis B virus and hepatitis C virus co-infection: still a challenge for the hepatologist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003637659

Coinfection with hepatitis B and C or B, C and delta viruses results in severe chronic liver disease and responds poorly to interferon-alpha treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003637659

Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003637659

EASL Clinical Practice Guidelines: management of chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003637659

Prophylaxis, diagnosis and therapy of hepatitis B virus (HBV) infection: the German guidelines for the management of HBV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003637659

Hepatitis B virus (HBV) DNA assays (methods and practical use) and viral kinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003637659

Treating viral hepatitis C: efficacy, side effects, and complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003637659

Combined interferon plus lamivudine treatment in young patients with dual HBV (HBeAg positive) and HCV chronic infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003637659

Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003637659

Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003637659

Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003637659

Hepatitis C virus eradication followed by HBeAg to anti-HBe seroconversion after pegylated interferon-alpha2b plus ribavirin treatment in a patient with hepatitis B and C coinfection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003637659

Sustained HCV-RNA response and hepatitis Bs seroconversion after individualized antiviral therapy with pegylated interferon alpha plus ribavirin and active vaccination in a hepatitis C virus/hepatitis B virus-coinfected patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003637659

The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated interferon-alpha2b and ribavirin in patients with HBV/HCV co-infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003637659

Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003637659

Late hepatitis B virus relapse in patients co-infected with hepatitis B virus and hepatitis C virus after antiviral treatment with pegylated interferon-a2b and ribavirin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003637659

10.1517/14656561003637659

21 January 2018

Identifiers

DOI

1 reference

22 August 2017

1 reference